Applied Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Applera Corp. unit submits 510(k) for ViroSeq HIV-1 genotyping system under FDA accelerated de novo review process, firm announces July 31. The system is designed to detect spontaneously-developed drug resistance in the HIV-1 virus genome by targeting protease and reverse transcriptase genes